By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that its DxS subsidiary has licensed a biomarker from Johns Hopkins University that it plans to use to develop PCR-based companion diagnostic tests for cancer.

Studies have shown that the PI3K gene that Qiagen licensed has mutations that could serve as predictive biomarkers for the success of some treatments for patients with lung, breast, colorectal, and other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.